
CHINA PHARMA HLDGS NEW Acción · US16941T2033 · CPHI · A3D7R6 (XASE) — cotizaciones en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak
Análisis impulsado por IA
Análisis fundamental
Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre CHINA PHARMA HLDGS NEW
Sin cotización
Precio de cierre XASE 01.05.2026:
0,53 USD
01.05.2026 19:53
Cotizaciones actuales de CHINA PHARMA HLDGS NEW
| Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
|---|---|---|---|---|---|
AMEX |
CPHI
|
USD
|
01.05.2026 19:53
|
0,53 USD
| -0,01 USD
-2,37 %
|
NYSE |
CPHI
|
USD
|
01.05.2026 19:53
|
0,53 USD
| -0,01 USD
-2,37 %
|
IEX |
CPHI
|
USD
|
23.04.2026 16:49
|
0,62 USD
| - |
Perfil de la empresa para CHINA PHARMA HLDGS NEW Acción
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
Datos de la empresa
Nombre CHINA PHARMA HLDGS NEW
Empresa China Pharma Holdings, Inc.
Símbolo CPHI
Sitio web
https://www.chinapharmaholdings.com
Mercado principal
Frankfurt
Frankfurt
WKN A3D7R6
ISIN US16941T2033
Tipo de valor Acción
Sector Healthcare
Industria Drug Manufacturers - Specialty & Generic
CEO Zhilin Li
País China
Moneda EUR
Empleados 0,2 T
Dirección No. 17, Jinpan Road, 570216 Haikou
Fecha de OPV 2002-04-17
Splits de acciones
| Fecha | Split |
|---|---|
| 15.04.2025 | 1:10 |
| 06.03.2024 | 1:5 |
| 06.03.2023 | 1:10 |
| 15.08.2003 | 250:5451 |
Cambios de identificador
| Fecha | De | A |
|---|---|---|
| 04.05.2006 | TSET | CPHI |
Símbolos de cotización
| Nombre | Símbolo |
|---|---|
| NYSE | CPHI |
Otras acciones
Los inversores que tienen CHINA PHARMA HLDGS NEW también tienen las siguientes acciones en su cartera:
